⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoride SCHEMBL28317693 | 1.00 | — | — | |
| SCHEMBL1372796 | 1.00 | — | — | |
| SCHEMBL745665 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL3992747 | 0.98 | — | — | |
| SCHEMBL31353035 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL12469432 | 0.98 | — | — | |
| SCHEMBL546913 | 0.93 | — | — | |
| SCHEMBL4492294 | 0.93 | — | — | |
| SCHEMBL18474377 | 0.93 | — | — | |
| Sulfuric Acid SCHEMBL28773568 | 0.91 | NOS2 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2547656-B1 | PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF | NOVARTIS AG (CH) | 2015-09-30 | — | — | EP | claimed |
| EP-2845593-A1 | Pyridine and pyrazine derivative for the treatment of chronic obstructive pulmonary disease | Novartis AG (CH) | 2015-03-11 | — | — | EP | claimed |
| US-20090076062-A1 | Organic Compounds | MAIBAUM JUERGEN KLAUS | 2009-03-19 | — | — | US | claimed |
| EP-1318148-B1 | Method of preparing optically pure (R)- or (S)- tetrahydrofuranyl ketone | SK CORP (KR) | 2005-01-12 | — | — | EP | claimed |
| US-6841688-B2 | Method of preparing optically pure (R)- or (S)- tetrahydrofuranyl ketone | SK CORPORATION (KR) | 2005-01-11 | — | — | US | claimed |
| US-20030114693-A1 | Method of preparing optically pure (R) - or (S) - tetrahydrofuranyl ketone | SK CORPORATION | 2003-06-19 | — | — | US | claimed |
| EP-1318148-A1 | Method of preparing optically pure (R)- or (S)- tetrahydrofuranyl ketone | SK Corporation (KR) | 2003-06-11 | — | — | EP | claimed |
| WO-2024175450-A1 | SUBSTITUTED S-ALANINATE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-29 | — | — | WO | disclosed |
| US-11911371-B2 | Pyridine and pyrazine derivative for the treatment of chronic bronchitis | NOVARTIS AG (CH) | 2024-02-27 | — | — | US | disclosed |
| US-20240058315-A1 | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis | NOVARTIS AG (CH) | 2024-02-22 | — | — | US | disclosed |
| US-11746091-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230033510-A1 | Compounds and Methods for Treatment of Visceral Pain | ARENA PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
| US-11214548-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20040077557-A1 | Macrolide antibiotics | GLAXO GROUP LIMITED (GB) | 2004-04-22 | — | — | US | disclosed |
| EP-1409466-A2 | HIV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THE SAME, THEIR PHARMACEUTICAL USES AND MATERIALS FOR THEIR SYNTHESIS | AGOURON PHARMACEUTICALS, INC. (US) | 2004-04-21 | — | — | EP | disclosed |
| EP-1380576-A1 | NOVEL 1H-INDAZOLE COMPOUND | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
| US-20030225071-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | PFIZER INC. | 2003-12-04 | — | — | US | disclosed |
| US-20030114693-A1 | Method of preparing optically pure (R) - or (S) - tetrahydrofuranyl ketone | SK CORPORATION | 2003-06-19 | — | — | US | disclosed |
| EP-1318148-A1 | Method of preparing optically pure (R)- or (S)- tetrahydrofuranyl ketone | SK Corporation (KR) | 2003-06-11 | — | — | EP | disclosed |
| WO-2002100844-A2 | HIV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THE SAME, THEIR PHARMACEUTICAL USES AND MATERIALS FOR THEIR SYNTHESIS | AGOURON PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |